Biotech developmental resources have a new brand: Cytiva
Now a Danaher Corp. asset, the former GE Healthcare Life Sciences business has been reshuffled
On April 1, having passed through governmental regulatory reviews, the acquisition of assets of GE Healthcare Life Sciences by Danaher Corp was formally completed. The new entity, part of Danaher’s “Life Sciences Platform” (which includes other brands like Beckman Coulter, Leica Microsystems and Pall Corp.) starts with annual sales of around $3 billion and 7,000 employees working in Europe, the US and China.
The original deal, announced just over a year ago, saw Danaher paying $21.4 billion for the assets. During regulatory review, Danaher agreed to sell off $750 million worth of assets to Sartorius; these included cell culturing materials and liquid chromatography equipment, representing annual sales of around $140 million.
According to a Cytiva press release, the company has a portfolio of products and services including instruments, consumables, digital and enterprise solutions and services for research, process development, and complete manufacturing workflows. Existing brands include ÄKTA, Amersham, Biacore, FlexFactory, HyClone, MabSelect, Sefia, Whatman, Xcellerex and Xuri. In 2019, more than 75% of the biological therapies approved by FDA relied on Cytiva's technologies for manufacturing.
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
